Checkpoint Inhibitor CTX-2026 Shows Promising Efficacy in Preclinical Study
News
Compass Therapeutics‘ CTX-2026, an antibody targeting the protein BTN3A1, could be therapeutic in ovarian cancer by helping the immune system destroy cancer cells, preclinical data show. The study, “BTN3A1 governs ... Read more